Building upon the microbiological foundations established in Part 1, this article evaluates the therapeutic potential of probiotics as adjuncts in the prevention and clinical management of col-orectal cancer (CRC). We detail the specific mechanisms through which beneficial strains—primarily from the Lactobacillus and Bifidobacterium genera—modulate the immune re-sponse, strengthen the intestinal barrier, and produce anti-cancer metabolites such as butyrate. The paper further contrasts the role of pathogenic bacteria, like Fusobacterium nucleatum, with the protective effects of next-generation probiotics. Additionally, we explore a holistic naturopathic framework, integrating dietary modifications and targeted supplementation to mitigate the side effects of conventional treatments like chemotherapy. Ultimately, this review advocates for an integrative oncological approach to improve clinical outcomes and enhance the quality of life for CRC patients.
Alves et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: